Birinci basamakta reçeteleme trendi ve sık karşılaşılan tanılara ait reçetelerin incelenmesi: Türkiye verisi

Yıl 2020, Cilt: 45 Sayı: 2, 695 - 708, 30.06.2020

Dilara Bayram , Caner Vızdıklar Volkan Aydın Fatma İşli Ahmet Akıcı

https://doi.org/10.17826/cumj.681368

Cited By: 3

Öz

Amaç: Bu çalışmada Türkiye’de birinci basamakta düzenlenen reçetelerin ayrıntılarının incelenmesi ve bunların yıllara göre değişiminin değerlendirilmesi amaçlandı.
Gereç ve Yöntem: Türkiye’de 2013-2016 tarihleri arasında birinci basamak hekimleri tarafından yazılan ve Reçete Bilgi Sistemi’nde kayıtlı tüm elektronik reçetelerdeki ilaçların ayrıntıları incelendi. Hastaların cinsiyetleri ve yaş grupları özelinde reçete başına düşen ortalama ilaç sayıları (RBDİS) belirlendi. İncelenen yıllarda en sık karşılaşılan ilk yirmi ilacın yer aldığı reçetelerin yüzdeleri belirlendi. Dört yıllık süreçte tek tanılı reçeteler içerisinde en sık karşılaşılan on tanının yer aldığı reçetelerin yüzdesi ve RBDİS incelendi.
Bulgular: Dört yılın toplamında 518.335.821 adet reçetede 1.457.034.275 kalem ilaç reçetelendiği ve RBDİS’nin 2,81 olduğu tespit edildi. Tüm yıllarda reçetelerde en fazla yer alan ilaçlar “diğer soğuk algınlığı preparatları” (%19,2-%19,7) ve “amoksisilin+beta-laktamaz inhibitörü” (%9,9-%10,5) idi. Dört yılın toplamında tek tanılı reçetelerde hipertansiyon (%6,9, RBDİS: 2,00) ve “akut üst solunum yolu enfeksiyonu, tanımlanmamış” (ÜSYE), (%6,5, RBDİS: 2,61) tanıları ilk sıralardaydı.
Sonuç: Birinci basamaktaki reçetelerin daha çok kadınlara ve yaşlılara yazıldığı ve ÜSYE ile hipertansiyon endikasyon alanlarında yoğunlaştığı anlaşılmaktadır. Soğuk algınlığı preparatları, NSAİİ’ler, PPİ’ler, analjezikler ve geniş spektrumlu antibiyotiklerin fazla reçeteleniyor olması birinci basamakta rasyonel reçeteleme davranışı ile ilgili önemli sorunların varlığına işaret etmektedir. 

Anahtar Kelimeler

İlaç kullanımı, birinci basamak, ulusal veri, elektronik reçete, trend analizi

Destekleyen Kurum

Çalışmamızda sponsor desteği yoktur.

Teşekkür

Verilerin sağlanmasına ve çalışmaya olan katkılarından dolayı Dr.Hakkı Gürsöz’e, Uzm. Ecz. Mesil Aksoy’a, End. Müh. Esma Kadı’ya ve diğer Türkiye İlaç ve Tıbbi Cihaz Kurumu ilgili çalışanlarına ve Prof. Dr. Ayşe Gelal’a teşekkür ederiz

Investigation of prescribing trends and prescriptions for common diagnoses in primary care: Nationwide data of Turkey

Öz

IPurpose: This study aimed to examine the details of prescriptions issued in primary care and the changes over the years in Turkey.
Materials and Methods: We analyzed all electronic prescriptions registered to Prescription Information System by primary care physicians in Turkey between 2013 and 2016. The mean number of drugs per prescription (nDPP) was determined by patients’ sex and age groups. The percentages of the prescriptions containing the top twenty most frequently encountered drugs were determined for each year of the study. In the four-year period, the percentage of prescriptions with the ten most common diagnoses among prescriptions with single diagnosis and nDPP were examined.
Results: A total of 1.457.034.275 drugs were prescribed in 518.335.821 prescriptions and nDPP was 2.81 for the four-year period. The most commonly used drugs in all prescriptions were “other cold preparations” (19.2-19.7%) and “amoxicillin+beta-lactamase inhibitor” (9.9-10.5%). The diagnosis of hypertension (6.9%, nDPP: 2.00) and “acute upper respiratory tract infection, unspecified” (URTI), (6.5%, nDPP: 2.61) were in the top ranks in single-diagnosis prescriptions during four-year period.
Conclusion: Primary care prescriptions appear to be mostly generated for women and elderly populations, with a tendency for URTI and hypertension indications. Overprescriptions of cold preparations, NSAIDs, PPIs, analgesics, and broad-spectrum antibiotics imply existence of important problems in the primary care regarding rational prescribing behavior. 

Anahtar Kelimeler

Drug utilization, primary care, national data, electronic prescription, trend analysis

Kaynakça

• 1. Akıcı A, Uzuner A. Birinci Basamak Sağlık Kurumlarında Çalışan Hekimlere Yönelik Akılcı İlaç Kullanımı. Ankara: Sosyal Güvenlik Kurumu; 2013.
• 2. World Health Organization. Using Indicators to Measure Country Pharmaceutical Situations: Fact Book on WHO Level I and Level II Monitoring Indicators. Geneva; 2006.
• 3. Doğukan M, Yer M, Kitiz B, Gülkan S. Akılcı İlaç Kullanımını Yaygınlaştırma Faaliyetlerine Sosyal Güvenlik Kurumunun Katkıları. Turkiye Klin J Pharmacol-Special Top. 2015;3(1):27-33.
• 4. Türkiye İstatistik Kurumu. Yıllara, yaş grubu ve cinsiyete göre nüfus, 1935-2018. http://www.tuik.gov.tr/PreIstatistikTablo.do?istab_id=1588. Accessed January 8, 2020.
• 5. Wettermark B, Vlahović‐Palčevski V, Lee D, Bergman U. Studies of Drug Utilization. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiology. Wiley; 2019:373-410.
• 6. Holloway KA, Ivanovska V, Wagner AK, Vialle-Valentin C, Ross-Degnan D. Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Trop Med Int Heal. 2013;18(6):656-664.
• 7. Mollahaliloglu S, Alkan A, Donertas B, Ozgulcu S, Akici A. Prescribing Practices of Physicians at Different Health Care Institutions. Eurasian J Med. 2013;45(2):92-98.
• 8. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: A QUALICOPC study. BMC Fam Pract. 2016;17(1):1-7.
• 9. Hobbs FDR, Bankhead C, Mukhtar T, et al. Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet. 2016;387(10035):2323-2330.
• 10. Wändell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G. Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011. Fam Pract. 2013;30(5):506-513.
• 11. Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ. 2008;337(nov24 2):a2245-a2245.
• 12. Thrane N, Sørensen HT. A one-year population-based study of drug prescriptions for Danish children. Acta Paediatr Int J Paediatr. 1999;88(10):1131-1136.
• 13. Al Balushi K, Al-Sawafi F, Al-Ghafri F, Al-Zakwani I. Drug utilization pattern in an Omani pediatric population. J Basic Clin Pharm. 2013;4(3):68.
• 14. Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: A repeated cross-sectional study. BMJ Open. 2015;5(9):1-7.
• 15. Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575-581.
• 16. Akıcı A. Akılcı ilaç kullanımı ilkeleri doğrultusunda yaşlılarda reçete yazma ve Türkiye’de yaşlılarda ilaç kullanımının boyutları. Geriatr Özel Sayı. 2006:19-27.
• 17. Türkiye Cumhuriyeti Sağlık Bakanlığı Refik Saydam Hıfzıssıhha Merkezi Başkanlığı Hıfzıssıhha Mektebi Müdürlüğü. Birinci Basamakta Akılcı Reçete Yazımı. Ankara; 2011.
• 18. Türkiye Cumhuriyeti Sağlık Bakanlığı. Sağlık İstatistikleri Yıllığı 2017. Ankara; 2018.
• 19. Haas JS, Phillips KA, Gerstenberger EP, Seeer AC. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med. 2005;142(11):1997-2000.
• 20. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. Türkiye İlaç Pazarı Gözlem Raporu-4: Satış Hacmi ve Değeri Açısından 2015 ve 2016 Yılı Pazar Durumu. Ankara; 2018.
• 21. T.C. Sosyal Güvenlik Kurumu. Sağlık Uygulama Tebliği (17.01.2020 Değişiklik Tebliği İşlenmiş Güncel 2013 SUT).; 2020.
• 22. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. 2014 Yılında Değer Bazında En Yüksek Satış Tutarına Sahi̇p İlk 100 İlacın Değerlendi̇ri̇lmesi̇ ve 2012-2013 Yılları İle Karşılaştırılması. Ankara; 2016.
• 23. McGettigan P, Henry D. Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. PLoS Med. 2013;10(2).
• 24. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug – drug interactions with over-the-counter NSAIDs. 2015:1061-1076.
• 25. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. Diklofenak İçeren Ürünler. Ankara; 2013.
• 26. Agency EM, Risk P, Committee A. New safety advice for diclofenac. Eur Med Agency. 2013;44(September):2-5.
• 27. Kristensen KB, Karlstad Ø, Martikainen JE, et al. Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000–2016: A Drug Utilization Study. Pharmacotherapy. 2019;39(2):150-160.
• 28. European Medicines Agency. Assessment Report for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Cardiovascular Risk. London; 2012.
• 29. Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84(6):1324-1334.
• 30. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: Systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:1-13.
• 31. Mash B, Fairall L, Adejayan O, et al. A morbidity survey of South African primary care. PLoS One. 2012;7(3).
• 32. Maç ÇE, Öztürk GZ. The Comparison of Patient Records Admitted to the Family Medicine Polyclinics of an Education and Research Hospital and an Educational Family Medicine Center. Ankara Med J. 2018;(1).
• 33. Gloth FM. Pain Management in Older Adults: Prevention and Treatment. J Am Geriatr Soc. 2001;49(2):188-199.
• 34. Witenko C, Moorman-Li R, Motycka C, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014;39(6):427-435.
• 35. Cohen SP, Mullings R, Abdi S. The pharmacologic treatment of muscle pain. Anesthesiology. 2004;101(2):495-526.
• 36. Kamath A. Thiocolchicoside: A review. DHR Int J Med Sci. 2013;4(2):39-45.
• 37. States M. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. 2014;44(January):1-3.
• 38. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu. Ek İzlemeye Tabi İlaçlar Listesi. https://www.titck.gov.tr/dinamikmodul/57?page=1. Accessed January 8, 2020.
• 39. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2017;37:19-24.
• 40. Moriarty F, Bennett K, Cahir C, Fahey T. Characterizing Potentially Inappropriate Prescribing of Proton Pump Inhibitors in Older People in Primary Care in Ireland from 1997 to 2012. J Am Geriatr Soc. 2016;64(12):e291-e296.
• 41. Eid SM, Boueiz A, Paranji S, Mativo C, Regina Landis BA, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561-2568.
• 42. Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther. 2018;43(1):65-72.
• 43. Skjødt MK, Ostadahmadli Y, Abrahamsen B. Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. Bone. 2019;120(April 2018):94-100.
• 44. Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot JF. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66(8):767-773.
• 45. Mangin D, Lawson J, Cuppage J, et al. Legacy drug-prescribing patterns in primary care. Ann Fam Med. 2018;16(6):515-520.
• 46. Bor S, Saritas Yuksel E. How is the gastroesophageal reflux disease prevalence, incidence, and frequency of complications (stricture/esophagitis/Barrett’s esophagus/ carcinoma) in Turkey compared to other geographical regions globally? Turkish J Gastroenterol. 2017;28(1):4-9.
• 47. Rui P, Okeyode T. National ambulatory medical care survey: 2016 National Summary Tabbles. Centers Dis Control Prev. 2016:1-11.
• 48. Collins R, Peto R, Hennekens C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
• 49. Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA - J Am Med Assoc. 2010;303(9):841-848.
• 50. Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393(10186):2155-2167.
• 51. Protty MB, Wilkins SJ, Hoskins HC, Dawood BB, Hayes J. Prescribing patterns of oral antiplatelets in Wales: Evolving trends from 2005 to 2016. Future Cardiol. 2018;14(4):277-282.
• 52. Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Reports. 2017;5:183-186.
• 53. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046.
• 54. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519-1528.
• 55. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381.
• 56. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol 140.; 2019.
• 57. Isbister GK, Prior F, Kilham HA. Restricting cough and cold medicines in children. J Paediatr Child Health. 2012;48(2):91-98.
• 58. European Medicines Agency. Codeine Not to Be Used in Children below 12 Years for Cough and Cold. London; 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_cough_or_cold_in_children/Position_provided_by_CMDh/WC500186159.pdf.
• 59. van Driel ML, Scheire S, Deckx L, Gevaert P, De Sutter A. What treatments are effective for common cold in adults and children? BMJ. 2018;363(October):k3786.
• 60. Mollahaliloǧlu S, Alkan A, Dönertaş B, Özgülcü Ş, Dilmen U, Akıcı A. Tek enfeksiyon tanılı reçetelere hekimlerin yazdığı antibiyotiklerin değerlendirilmesi. Marmara Pharm J. 2012;16(3):206-212.
• 61. Isler B, Keske S, Aksoy M, et al. Antibiotic overconsumption and resistance in Turkey. Clin Microbiol Infect. 2019;25(6):651-653.
• 62. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother. 2014;69(1):234-240.
• 63. Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832-840.
• 64. World Health Organization. The Top 10 Causes of Death - Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva; 2018. https://www.who.int/healthinfo/global_burden_disease/GHE2016_Deaths_Global_2000_2016.xls. Accessed January 6, 2020.
• 65. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA - J Am Med Assoc. 2014;311(5):507-520.
• 66. Wiliams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;(August):1-98.
• 67. Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015;16(1).
• 68. Sundbøll J, Adelborg K, Mansfield KE, Tomlinson LA, Schmidt M. Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark. Am J Cardiol. 2017;120(12):2193-2200.